Neurocrine Biosciences (NBIX) update #9
Posted by intelledgement on Tue, 02 Sep 08
Our #2 development-stage biopharma company, Neurocrine Biosciences (NBIX), today announced positive results from the first of three phase 2 trials of their orally-active nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix, in patients with endometriosis. Patients took elagoix daily for six months—either a 150 mg dose once a day or a 75 mg dose twice a day (plus a third arm treated with the current standard of care: Pfizer’s DMPA). Patients in both elagolix arms had reductions in symptoms that were comparable to the DMPA arm but with low bone mineral density loss.
According to the press release, CEO Kevin Gorman stated, “We couldn’t be more pleased with the results of this study. We began this program nine years ago with the hope of selectively modulating the GnRH system with an oral antagonist. This trial and our previous Phase II studies have now shown that this is possible. Elagolix is a first in class drug for endometriosis sufferers who desperately need a safe and effective therapy. This is apparent from the 8,000 inquiries to the call center for just this one study.” About 89 million women worldwide suffer from endometriosis, including about seven million in the USA.
There are two more phase 2 studies currently ongoing for elagolix.